Compare APPS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | MRVI |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | APPS | MRVI |
|---|---|---|
| Price | $4.63 | $3.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $6.25 | $4.58 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $525,092,000.00 | $192,435,000.00 |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $11.83 | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.82 | N/A |
| 52 Week Low | $1.40 | $1.67 |
| 52 Week High | $8.28 | $6.21 |
| Indicator | APPS | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 39.39 | 54.35 |
| Support Level | $4.57 | $3.50 |
| Resistance Level | $5.13 | $3.95 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 23.08 | 48.03 |
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.